Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	1999-2001
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	12
DOIs	https://doi.org/10.1016/j.jtho.2021.07.034
State	Published - Dec 2021

Access to Document

@article{1661456d7078486984f9d7fc866cf0bf,

title = "Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation",

author = "Daniel Morgensztern and Ramaswamy Govindan",

year = "2021",

month = dec,

doi = "10.1016/j.jtho.2021.07.034",

language = "English",

volume = "16",

pages = "1999--2001",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "12",

}

TY - JOUR

T1 - Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

AU - Morgensztern, Daniel

AU - Govindan, Ramaswamy

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85119319914&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2021.07.034

DO - 10.1016/j.jtho.2021.07.034

M3 - Editorial

C2 - 34809804

AN - SCOPUS:85119319914

SN - 1556-0864

VL - 16

SP - 1999

EP - 2001

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 12

ER -